The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail info@hpra.ie


Eribulin Advanz Pharma 0.44 mg/ml solution for injection



Advanz Pharma LimitedPA23450/001/001

Main Information

Trade NameEribulin Advanz Pharma 0.44 mg/ml solution for injection
Active SubstancesEribulin mesylate
Dosage FormSolution for injection
Licence HolderAdvanz Pharma Limited
Licence NumberPA23450/001/001

Group Information

ATC CodeL01XX41 eribulin

Status

License statusAuthorised
Licence Issued22/09/2023
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of LicenceMedicinal product subject to restricted medical prescription (See: Summary of Product Characteristics, section 4.2)
Marketing StatusNot marketed

Documents

Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available
« Back